It’s only fair to share… Catadegbrutinib CAS 2736508-60-2 MF C47H54N12O4 MW851.0 g/mol 1,2,4-Oxadiazole-5-carboxamide, 3-(1,1-dimethylethyl)-N-[(1R)-1-[2-methyl-4-[6-[6-[4-[[1-[4-(tetrahydro-2,4-dioxo-1(2H)-pyrimidinyl)phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-3-pyridinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]ethyl]- 3-tert-butyl-N-[(1R)-1-[4-[6-[6-[4-[[1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-pyridinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylphenyl]ethyl]-1,2,4-oxadiazole-5-carboxamide 3-tert-butyl-N-{(1R)-1-[13-methyl-82,84-dioxo-27H-2(4,6)-pyrrolo[2,3-d]pyrimidina-8(1)-[1,3]diazinana-4(1,4)-piperazina3(5,2)-pyridina-6(4,1)-piperidina-1(1),7(1,4)-dibenzenaoctaphan-14-yl]ethyl}-1,2,4-oxadiazole-5-carboxamideBruton tyrosine kinase degrader, antineoplastic, BGB-16673, BGB 16673, PF6GPZ4DYT, BTK-IN-29, Tacabrutideg Catadegbrutinib (BGB-16673) is an orally active, potent Bruton’s tyrosine kinase (BTK) degrader, or chimeric degradation activator compound (CDAC). It works by targeting BTK for proteasomal degradation, showing high efficacy against wild-type and mutated forms (including C481S) …
Author archives
Bretisilocin
It’s only fair to share… Bretisilocin CAS2698331-35-8 MF C13H17FN2 MW220.29 g/mol N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amineserotonin (5-HT2A) receptor agonist, GM-2505, GM 2505, 5-Fluoro-N-methyl-N-ethyltryptamine, 5F-MET, 5-F-MET, 5-Fluoro-MET, DS425RQ8SX Bretisilocin, also known by its developmental code name GM-2505 and as 5-fluoro-N-methyl-N-ethyltryptamine (5F-MET or 5-fluoro-MET), is a serotonergic psychedelic of the tryptamine family which is under development for the treatment of major depressive disorder.[1][7][2][3] It is an analogue of dimethyltryptamine (DMT) and is the 5-fluorinated derivative of methylethyltryptamine (MET).[8] Bretisilocin’s route of administration is intravenous infusion.[1][2][3][4] The …
Blixeprodil
It’s only fair to share… Blixeprodil CAS 2881017-49-6 MF C13H16FNO MW 221.27 g/mol Cyclohexanone, 2-(4-fluorophenyl)-2-(methylamino)-, (2R)- (2R)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-oneN-methyl-D-aspartate (NMDA) receptor antagonist, GM-1020, GM1020, (R)-4-Fluorodeschloroketamine, (R)-4-FDCK, (R)-4FDCK, S2MGG2PC5K Blixeprodil,[5] also known by its developmental code name GM-1020 or as (R)-4-fluorodeschloroketamine ((R)-4-FDCK), is an NMDA receptor antagonist related to ketamine which is under development for the treatment of major depressive disorder, bipolar depression, and other depressive disorders.[1][6][2][3][7][8] It is taken by mouth.[1][2][3] The …
Birelentinib
It’s only fair to share… Birelentinib CAS 2662512-15-2 MF C23H21F2N5O3 MW453.4 g/mol [(2S,5S)-5-[4-amino-5-[4-(2,3-difluorophenoxy)phenyl]imidazo[5,1-f][1,2,4]triazin-7-yl]oxan-2-yl]methanol [(2S,5S)-5-{4-amino-5-[4-(2,3-difluorophenoxy)phenyl]imidazo[5,1-f][1,2,4]triazin-7-yl}oxan-2-yl]methanoltyrosine kinase inhibitor, antineoplastic, DZD8586, DZD 8586, Fast Track designation, BTK-IN-30, Z2F599L9GD Birelentinib (also known as DZD8586) is a first-in-class, non-covalent dual inhibitor of LYN (lymphocyte-specific protein tyrosine kinase) and BTK (Bruton’s tyrosine kinase). It is currently being developed by Dizal Pharmaceutical as an oral therapy for various B-cell malignancies. Clinical Status …
Betovumeline
It’s only fair to share… Betovumeline CAS 1314018-44-4 MF C8H11N3O MW 165.19 g/mol (1R,5R)-1-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.1.0]hexane (1R,5R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.1.0]hexanemuscarinic receptor agonist, ML 007, MPL 0527, 5UXW4B47R9 Betovumeline (also known as ML-007 or MPL-0527) is a muscarinic receptor agonist currently being developed for the treatment of neurological and neuropsychiatric disorders. It is specifically designed to target muscarinic receptors in the brain, which play a critical …
Becondogrel
It’s only fair to share… Becondogrel CAS 1416696-44-0 MF C16H16ClNO3S, MW 337.821 2-OXO-CLOPIDOGREL, (.ALPHA.S,7AS)- (4S)-2-Oxoclopidogrel THIENO(3,2-C)PYRIDINE-5(4H)-ACETIC ACID, .ALPHA.-(2-CHLOROPHENYL)-2,6,7,7A-TETRAHYDRO-2-OXO-, METHYL ESTER, (.ALPHA.S,7AS)- Methyl (S)-(2-chlorophenyl)[(7aS)-2-oxo-2,6,7,7atetrahydrothieno[ 3,2-c]pyridin-5(4H)-yl]acetate methyl (S)-(2-chlorophenyl)[(7aS)-2-oxo-2,6,7,7atetrahydrothieno[3,2-c]pyridin-5(4H)-yl]acetateplatelet aggregation inhibitor, D7X6820P1N, Copidogrel oxide, (4S)-2-Oxoclopidogrel Becondogrel is an antiplatelet medication and an irreversible P2Y12 receptor antagonist. It is chemically known as 2-oxoclopidogrel, which is a direct metabolic intermediate of the widely …
Balomenib
It’s only fair to share… Balomenib CAS 2939850-17-4 MF C33H34F3N7O2 MW617.7 g/mol 4-methyl-1-[[(2S)-5-oxomorpholin-2-yl]methyl]-5-[[2-[6-(2,2,2-trifluoroethyl)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl]methyl]indole-2-carbonitrile 4-methyl-1-{[(2S)-5-oxomorpholin-2-yl]methyl}-5-({2-[6-(2,2,2-trifluoroethyl)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl}methyl)-1H-indole-2-carbonitrilemenin inhibitor, antineoplastic, ZE63-0302, 3BEG4BWN8E Balomenib (also known as ZE63-0302) is an oral, small-molecule menin inhibitor currently in clinical development for metabolic and oncological conditions. It works by disrupting the protein-protein interaction between menin and KMT2A (formerly MLL), a mechanism that plays a critical role in both pancreatic beta-cell function and certain …
Atebimetinib
It’s only fair to share… Atebimetinib CAS 2669009-92-9 MF C23H27FN4O6S MW506.5 g/mol [4-[(dimethylamino)methyl]-3-[[2-fluoro-3-(methylsulfamoylamino)phenyl]methyl]-2-oxochromen-7-yl] N,N-dimethylcarbamate 4-[(dimethylamino)methyl]-3-({2-fluoro-3-[(methylsulfamoyl)amino]phenyl}methyl)-2-oxo-2H-1-benzopyran-7-yldimethylcarbamateMEK tyrosine kinase inhibitor, antineoplastic, IMM-104, IMM 104, Fast Track designation, TEL9243A3N Atebimetinib (IMM-104) is an investigational oral, deep cyclic inhibitor (DCI) that targets the MAP kinase (MAPK) pathway in solid tumors, particularly RAS-mutant pancreatic cancer. Designed for rapid, pulsatile inhibition to minimize resistance …
Anvumetostat
It’s only fair to share… Anvumetostat CAS 2790567-82-5 MF C22H19F3N4O3 MW444.4 g/mol (4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]methanone (4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl){(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl}methanoneantineoplastic, AMG 193, QAT649EJ5E, PRMT5-IN-27, Anvumetostat (also known as AMG 193) is an orally available, small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), primarily being developed for the treatment of advanced solid tumours with MTAP-null (methylthioadenosine phosphorylase-deficient) mutations. Mechanism of Action Clinical Development Anvumetostat was initially developed by Amgen, …
Andamertinib
It’s only fair to share… Andamertinib CAS 2254145-43-0 MF C31H36N8O3 MW568.7 g/mol N-[4-methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-[[6-(1-methylindazol-5-yl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide N-(4-methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-{[6-(1-methyl-1H-indazol-5-yl)pyrimidin-4-yl]amino}phenyl)prop-2-enamideepidermal growth factor receptor tyrosine kinase inhibitor, antineoplastic, PLB 1004, 5X3KAG7ZBW Andamertinib (also known as PLB1004) is an investigational, orally bioavailable, and irreversible small-molecule inhibitor of the epidermal growth factor receptor (EGFR). It is primarily being developed to treat non-small cell lung cancer (NSCLC) with …